Real World Evaluation of Lifelight®: A Contactless Vital Signs Monitor for Self-monitoring Blood Pressure and Its Comparison to Standard of Care (VISION-RWE)

VISION-Real World Evaluation

A randomised controlled trial for comparison of real-world feasibility and clinical outcomes of two different methods of home blood pressure monitoring Participants aged 18 years or over with diagnosed and treated hypertension (including via lifestyle interventions) that is not controlled (i.e. in-clinic measurement is 140/90 mmHg or greater) will be recruited from hypertension hospital clinics

Study Overview

• Status: Recruiting
• Conditions: Hypertension
• Intervention / Treatment: Device: Blood Pressure Cuff; Device: Lifelight

Detailed Description

Suitable patients from the BHT hypertension clinic patient database will be invited to take part in the study, resulting in the recruitment of 500 people aged 18 years or over who have a clinical diagnosis of hypertension that is treated (including via lifestyle interventions) but not controlled (≥140/90mmHg in-clinic measurement of BP). Study nurses at BHT will facilitate this recruitment and randomise participants to either Lifelight® or BP cuff arm using a secure web-based system in 1:1 ratio, minimised on baseline BP, gender, and BP target (standard hypertension, older hypertension and diabetes). They will also collect all baseline study data, including baseline BP measurements.

The HBPM schedule that all participants will be asked to follow for the full 6-month study duration is HBPM using BP cuff or Lifelight® (depending on into which arm of the study they have been randomised) twice in a sitting for two sittings a day for one week every month. All participants will be asked to record their adherence to HBPM in the provided diary (recording the number of repeat measurements made on each day that those measurements are made and notes about any measurement failures). They will also be requested to record in their diary information about their healthcare resource use (GP appointments, outpatients' appointments, hospitalisations, medication and dose changes, medication adherence) and feedback about their HBPM method every month. All participants will also be asked to complete a set of tailored and validated questionnaires in the provided questionnaire booklet: quality of life.

The diaries and questionnaire booklets include instructions to assist with their accurate completion by participants. Participants will be issued with two diaries during their study participation: one at the baseline visit and one at the 3-month visit. They should complete the diary every day that they are doing HBPM. Participants will be issued with 3 questionnaire booklets during their study participation: two at the baseline visit and one at the 3-month visit. They should complete one questionnaire booklet within one week of their baseline visit, the second booklet within one week of their 3-month visit, and the third booklet within one week of their 6-month visit. Participants will be requested to bring back the diary and questionnaire booklet(s) at their subsequent study visit at BHT. Participants randomised to the Lifelight® arm will be prompted via the app to monitor their BP during the relevant weeks.

People eligible to take part in this study will be adults (18+ years old) with treated but uncontrolled hypertension. People with uncontrolled hypertension have the highest risk of CVD events and therefore the value of HBPM could be greatest for these people. The TASMIN and HOME BP studies focussed on this sub-population of patients with hypertension too, suggesting that future guidelines may continue to provide no recommendation of frequent HBPM for people with controlled hypertension, but a change to the guidelines for people with uncontrolled hypertension.

• Study Type: Interventional
• Enrollment (Estimated): 500
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Laurence Pearce, BSc, MBA; Phone Number: 07803950356; Email: laurence@xim.ai
• Study Contact Backup: Name: Gauri Misra, BDS, MSc.; Phone Number: 07880228126; Email: gauri.misra@xim.ai

Study Locations

• United Kingdom
  • London, United Kingdom, EC1M 6BQ
    • Recruiting
    • William Harvey Heart Centre, Queen Mary Queen Mary University of London, Charterhouse Square,
    • Contact: Manish Saxena, MBBS; Phone Number: 020 7882 3856; Email: m.saxena@qmul.ac.uk
    • Contact: Armida Balawon, RN; Phone Number: 020 7882 5660; Email: a.balawon@qmul.ac.uk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 18 years or older
• Established diagnosis of hypertension
• Uncontrolled hypertension defined as office blood pressure ≥140/90mmHg.
• Patients who are pharmacologically treated for their hypertension should have been on stable medication for at least 4 weeks.
• Ability to read, write and understand English to complete the study.
• Capacity to give free, valid informed consent.
• A compatible device that supports Lifelight®, as per xim Ltd.'s constantly updating list of compatible devices. If this is not possible, xim Ltd, might provide a similar device for the purpose of the study.

Exclusion Criteria:

• Patients with stage III hypertension with office blood pressure ≥180/120mmHg or it is unsafe to keep them in the study, in the opinion of the investigators.
• Individuals with diagnosed atrial fibrillation.
• Patients with significant arrhythmias such as SVT (Supraventricular tachycardia) or any rhythm that has significant impact on their BP, poor perfusion, pregnancy, pre-eclampsia, deformities or abnormalities which may prevent proper application of a BP cuff, or skin disorders (anaemia, jaundice, rosacea, psoriasis, acute acne, and erythropoietic protoporphyria)
• Participants who are unwilling to undertake self-monitoring or lacking capacity.
• Partners or spouses of individuals already randomised in the trial
• Patients on dialysis or known ESRD (End-stage kidney disease)
• Patients on active cancer treatment
• Terminally ill patients
• Patients who cannot tolerate sitting for up to one hour.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Cuff Arm; Blood Pressure Cuff	Device: Blood Pressure Cuff; Standard Blood Pressure Cuff Digital
Experimental: LifeLight Arm; Contactless Vital Signs Monitor using RPPG	Device: Lifelight; Contactless Vital Signs Measurement via RPPG

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood Pressure Measurement Non Inferiority	Demonstrate non-inferiority of Lifelight® HBPM compared to cuff-based HBPM for achieving blood pressure control. (5 mmHg non-inferiority margin)	3 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adherance to Blood Pressure Measurement	Determine acceptability and adherence of Lifelight® for HBPM in comparison to cuff-based HBPM methods.	6 Months

Collaborators and Investigators

• Sponsor: Xim Limited
• Collaborators: Barts & The London NHS Trust; Mind Over Matter Medtech Ltd; Health Innovation Wessex

Study record dates

Study Major Dates

• Study Start (Actual): February 10, 2025
• Primary Completion (Estimated): October 31, 2025
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: January 24, 2024
• First Submitted That Met QC Criteria: March 15, 2024
• First Posted (Actual): March 22, 2024

Study Record Updates

• Last Update Posted (Actual): April 3, 2025
• Last Update Submitted That Met QC Criteria: March 28, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Hypertension
• Other Study ID Numbers: IRAS ID:321955

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No